intrommune_icon_500x500.png
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
May 21, 2024 09:35 ET | Intrommune Therapeutics
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
intrommune_icon_500x500.png
Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya
March 12, 2024 11:01 ET | Intrommune Therapeutics
Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.
intrommune_icon_500x500.png
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
February 22, 2024 09:34 ET | Intrommune Therapeutics
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects
AAFA Statement on Uber Eats Super Bowl Ad
AAFA Statement on Uber Eats Super Bowl Ad
February 08, 2024 15:20 ET | Asthma and Allergy Foundation of America
Washington, DC, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) issued the following statement which may be attributed to Kenneth Mendez, president and CEO:  ...
intrommune_icon_500x500.png
Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 06, 2024 09:34 ET | Intrommune Therapeutics
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy
Global Allergy Vaccine Market
Global Allergy Vaccine Market Report 2023: A $1.33 Billion Market in 2022 - Industry Size, Share, Trends, Opportunities, and Forecasts, 2018-2028F
January 24, 2024 05:03 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's...
intrommune_icon_500x500.png
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
January 08, 2024 09:05 ET | Intrommune Therapeutics
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy
22157.jpg
Global Peanut Allergy Treatment Market Report 2024: Analysis by Drug Class, Antihistamines, Epinephrine - Forecasts to 2030
January 05, 2024 09:03 ET | Research and Markets
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Peanut Allergy Treatment Market Size, Share & Trends Analysis Report by Drug Class (Antihistamines, Epinephrine), Route Of Administration,...
intrommune_icon_500x500.png
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
November 09, 2023 11:01 ET | Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
Logo.png
Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies - Vedanta, Allergy, COUR Pharmaceutical, DBV, Aimmune, Novartis, NIAID, Alladapt Immunotherapeutics
September 12, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies - Vedanta, Allergy, COUR Pharmaceutical, DBV,...